Medtronic launches leonine pump education effort

Share this article:
Medtronic launches leonine pump education effort
Medtronic launches leonine pump education effort
Medtronic launched a video contest aimed at diabetic kids, who use an insulin pump, and their parents.

The contest features Lenny the Lion, a character that Medtronic has used for children's diabetes education in Europe and is now introducing in the US. Contestants must download and print out a kit containing cutouts of Lenny and incorporate them into their 2-3 minute videos depicting Lenny educating children about diabetes. The last day for submissions is March 1, and shortlisted videos will be posted for voting later in the month.

The contest does not mention any products. Medtronic makes the Paradigm Real-Time insulin pump, which holds upwards of two-thirds of the US market and around 60% of the global market.

In costume form, Lenny looks a little like he fell off The Wiggles tour bus. The story goes that he was diagnosed with diabetes at a young age and uses an insulin pump. Medtronic said he'll soon have his own US website and iPhone apps, and will be putting in appearances at diabetes camps, conferences and pediatric clinics.

"We chose the lion character because Lenny represents a brave, courageous and active figure that is at the same time a cuddly figure that kids can relate to," said a Medtronic spoke. "The idea is that Lenny teaches kids how to live a healthy and active life even with diabetes."
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...